On September 19, 2023, Taysha Gene Therapies revealed its plans to explore external strategic opportunities for the TSHA-120 program, aiming to facilitate additional progress in the treatment of Giant Axonal Neuropathy (GAN). This strategic decision will not only ensure the availability of funds but also extend the company’s financial runway until the fourth quarter of 2025. The primary objective behind this extended cash runway is to support the ongoing clinical development of TSHA-102, a groundbreaking self-complementary intrathecally delivered AAV9 gene replacement therapy specifically designed for individuals suffering from Rett syndrome.
Taysha Gene Therapies, Inc.
Updated on: 19/09/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Neutral
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
4:00 AM (UTC)
Date:19 September, 2023
|Analyst / firm||Rating|
TSHA Stock Analysis: Impressive Earnings Growth but Modest Outlook for the Next Five Years
On September 19, 2023, TSHA stock opened at $3.10 and traded between $3.06 and $3.28. The trading volume for the day was 87,884 shares, significantly lower than the average volume over the past three months. TSHA has a market capitalization of $613.2 million and has shown impressive earnings growth in the previous year and current year. However, the projected earnings growth for the next five years is modest. TSHA has a price/sales ratio of 39.70 and a price/book ratio of 218.52, indicating that the stock may be trading at a premium. TSHA is scheduled to report its next earnings on November 8, 2023, with a current EPS forecast of -$0.28. The company generated annual revenue of $2.5 million in the previous year but incurred a significant loss of -$166.0 million, resulting in a net profit margin of -6,635.25%. No information is available about the company’s management and headquarters.
Taysha Gene Therapies Inc (TSHA) Stock Price Shows Positive Performance and Consensus Buy Rating
On September 19, 2023, Taysha Gene Therapies Inc (TSHA) experienced a positive performance in its stock price. The company’s stock had a median target price of $6.00, with a high estimate of $8.00 and a low estimate of $2.00. This median estimate represents an increase of 85.19% from the last recorded price of $3.24.
Nine analysts provided these 12-month price forecasts for TSHA, and all of them recommended buying the stock. This consensus rating has remained steady since July, indicating a consistent positive sentiment among investment analysts.
Taysha Gene Therapies Inc is a company focused on developing and commercializing gene therapies for the treatment of severe genetic diseases. The company’s current quarter earnings per share stood at -$0.28, and its sales for the same period amounted to $2.4 million. The reporting date for these figures is set for November 8.
Investors and analysts seem optimistic about the future prospects of TSHA, as reflected in the positive stock performance and the consensus buy rating. However, it is important for investors to conduct thorough research and consider various factors before making any investment decisions.